Brammer Bio is ready to manufacture cell and gene therapy products at newly completed facility.
Gene therapy CDMO Brammer Bio has completed renovations and upgrades to its cGMP manufacturing site in Cambridge, Massachusetts, the facility it acquired last January from Biogen. According to Brammer’s recent announcement, the site’s operations are ready to manufacture gene therapy products commercially for clients.
Located near Kendall Square, the facility was previously licensed by regulators to produce protein-based therapeutics. The facility houses state-of-the-art cleanroom suites configured and outfitted to, “accommodate a broad-range of gene therapy manufacturing process technologies.”
After acquiring the 66,000 square-foot facility from Biogen 10 months ago, Brammer Bio on-boarded 100 experienced employees. Since the acquisition, Brammer has added another 50 people to the site’s professional staff in order to support leveraging the facility’s “large-scale adherent and stirred tank production, automated fill/finish system leveraging isolator technology, quality control laboratories and process development space.”
Mark Bamforth, President and CEO of Brammer explained: "Our Cambridge site underwent a remarkable transformation. We converted the former biologics manufacturing space that once produced some of the first antibody-based therapies into a facility that now produces leading edge gene therapy products using a variety of manufacturing platforms."
The company has also acquired another 49,000 square feet of warehousing capacity in Somerville, Massachusetts to support distribution and storage of client products. Also, as of September Brammer has completed the doubling of its early-phase clinical manufacturing capacity in Florida.
Christopher Murphy, Brammer’s Chief Manufacturing Officer remarked that the company’s recent momentum is founded on its scientific and manufacturing experience. "That foundation is supported by Brammer's investment of over $50 million in expanding its CDMO services. Today, we offer clients access to capacity at a variety of scales, and with a personalized manufacturing approach that is focused on safety, quality, process robustness, and fulfillment of their product goals."
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.